

Hydroxychloroquine; Why It Might Be Successful and Why It Might Not Be Successful in The Treatment of Covid-19 Pneumonia?

Could It Be A Prophylactic Drug?

Omer Deniz, MD

Pulmonologist

Professor in Pulmonary Medicine,

Burc Mahallesi, Yenimahalle, Ankara, Turkey

E-mail: omerdeniz@yahoo.com

Abstract

According to current literature and preliminary data, hydroxychloroquine (HCQ) seems potentially effective in treating patients with Covid-19 pneumonia. The concentrations of the HCQ in the lungs might be well above that of plasma. Most likely, this property of HCQ provides effective drug concentrations. HCQ has a gradual onset of action in the treatment of rheumatic diseases. This could be valid for the treatment of Covid-19 pneumonia. Reduced perfusion, somewhat distorted architecture of lung tissue and edema might reduce HCQ accumulation in pneumonic areas of the lungs in Covid-19 pneumonia. Patients having extensive lung involvement might have less HCQ concentrations in their lungs than that of patients having limited lung involvement. Furthermore, patients having extensive lung involvement might have more viral load than that of limited lung involvement. That's why HCQ might be more effective in the treatment of mild and moderate Covid-19 pneumonia cases and might not be effective in advanced cases. Using HCQ in Covid-19 prophylaxis seems logical since providing enough accumulation of HCQ in the

healthy lungs before the arrival of the SARS-CoV-2 virus, might prevent Covid-19 pneumonia. The purpose of this paper is not to recommend using or not using HCQ for the treatment or for the prophylaxis of Covid-19 pneumonia. The purpose of this paper is only to try to bring a new perspective on the role of HCQ in the treatment or in the prophylaxis of Covid-19 pneumonia. This paper proposes only hypotheses, which need further researches to be confirmed.

Keywords: hydroxychloroquine; COVID-19; pneumonia; prophylaxis

Introduction

Even though there is no double blind randomized placebo-controlled studies, according to current literature and preliminary data, mainly composed of cell culture, animal and small-uncontrolled human studies, hydroxychloroquine (HCQ) seems potentially effective in treating patients with Covid-19 pneumonia¹⁻⁵. It is very well known that, in normal conditions, no drug can be approved for the treatment of human-beings based on the evidence originating only from cell cultures, animal studies or uncontrolled small studies with the absence of phase I, II, III drug studies. Since HCQ is an old drug and repurposed for treatment of Covid-19 disease, phase I studies, maybe, phase II studies might not be necessary in normal conditions. Furthermore, it is almost impossible to determine an exact drug dosage to clear the virus from the body based on the animal or cell culture studies^{3,6,7}. However, since there is an urgent pandemic situation, even in the absence of sufficient scientific evidence, the role of HCQ in the treatment of Covid-19 pneumonia is debated among many experts. Some experts advocate to use HCQ with some precautions or case by case, some advocate waiting for the results of ongoing HCQ-Covid-19 trials, some find its use

potentially harmful^{8, 9}. On the other hand, in practice, HCQ is commonly used for the treatment of Covid-19 disease worldwide. Its use is recommended in interim guidelines of Turkey¹⁰ and Belgium¹¹ mostly as the first line treatment of mild and moderate Covid-19 pneumonia cases. It is also recommended as a prophylactic drug for Covid-19 disease in India¹².

Mechanism of Action and Pharmacokinetics of HCQ

HCQ is believed to show its antiviral activity against SARS-CoV-2 virus at least by two ways, first by interfering with the glycosylation of ACE2 receptor, thus reducing the ability of the SARS-CoV-2 virus to bind on the ACE2 receptors existing on the surface of the host cells, second increasing the endosomal pH which blocks further stages of viral replication¹⁻³. In addition, since HCQ might be a zinc ionophore and zinc might have some antiviral effects^{13,14} it might also be hypothesized that addition of zinc to HCQ therapy might be more effective than HCQ alone¹⁵. However, data about HCQ plus zinc therapy for Covid-19 disease is very limited for now.

Hydroxychloroquine (HCQ) has a large volume of distribution. It is believed that mainly tissue accumulation is responsible for the large volume of distribution of HCQ. Current literature indicates that tissue concentrations of HCQ are well above the plasma concentrations. The concentrations of the HCQ in the lungs might be 200-700 times greater than the plasma concentrations. HCQ accumulates in great amounts in liver, kidneys, lungs and other organs or tissues^{2,3,16-18}. Most likely, this property of HCQ provides effective viral inhibiting drug concentrations in tissues¹⁻³. In addition, since HCQ is a weak base, it accumulates in acidic compartments in the body mainly in lysosomes and inflamed tissues^{1,2,16,19-23} which might constitute the majority of the tissue concentration of the drug that might also enable HCQ to block SARS-CoV-2

virus replication¹⁻³. HCQ could be transported into tissues by lymphocytes, leukocytes or monocytes since HCQ can also accumulate in these cells^{16,19,24}. The plasma concentrations of HCQ are well below the inhibitory levels of SARS-CoV-2 virus. The elimination half-life of HCQ is shown to be very long which might mainly be attributed to slow releasing of HCQ from the drug-accumulated tissues into the blood^{2,16-18}. It was also shown that the bioavailability of the HCQ might be variable among patients^{18,20,22,23}.

Background of Hypothesis

Currently, HCQ is used mainly for the treatment of rheumatic diseases. In the context of rheumatology, HCQ has a gradual onset of action that is HCQ is a slow acting anti rheumatic drug and, it may take several weeks to show its action however full therapeutic efficacy may be seen after a few to several months of therapy²⁰⁻²³. Steady state drug levels can be achieved using regular daily HCQ doses after several weeks. This is mainly determined by the complex interaction among absorption, distribution, metabolism and elimination of HCQ. Since HCQ have a large volume of distribution, tissue accumulation might be considered as one of the major determinants of these factors. Thus the delayed effect of HCQ in rheumatic diseases can be mainly attributed to its slow accumulation in the tissues²⁰⁻²³. Gradual onset of action of HCQ could also be valid for Covid-19 pneumonia treatment, thus a considerably long time might be needed for HCQ to achieve therapeutic drug concentrations in lungs, that's why starting HCQ therapy as early as possible seems logical.

Small thrombi, vascular injury, interstitial fibrosis, vascular wall thickening, lumen stenosis and occlusion, diffuse alveolar damage, thickened alveolar capillaries,

edema, fibrin thrombi in capillaries and small vessels, and inflammatory cells in diseased areas of the lungs might be seen in Covid-19 pneumonia patients^{25,26}. According to histopathological findings, some pulmonary capillaries and some small vessels seem involved (partially) as wall thickening, fibrin thrombi, thrombi, vascular stenosis and occlusion in Covid-19 pneumonia. These abnormalities might cause poor perfusion of diseased lung areas²⁵⁻²⁸. Hypoxic pulmonary vasoconstriction might also contribute to reduced pulmonary perfusion²⁷. Reduced perfusion, pulmonary edema and somewhat distorted architecture of lung tissue might reduce the drug delivery into these pneumonic areas. Eventually drug concentrations in the pneumonic areas of the lungs might be reduced even though HCQ is prone to accumulate in (acidic) inflamed tissues due to its weak base property¹⁹⁻²³. Since one of the main suggested mechanisms of Covid-19 pneumonia is the attack of SARS-CoV-2 virus to ACE2 receptors on the surface of type-2 pneumocytes²⁹ less HCQ arrival and accumulation in and around these cells might result in inefficient drug concentrations and treatment failure.

Considering reduced drug concentrations in the pneumonic areas of the lungs together with HCQ's large volume of distribution, its huge uptake by the tissues, in the context of covid-19 pneumonia particularly by the lungs, it might be supposed that in a given HCQ dose, the amount of HCQ in healthy lungs is not comparable to the amount of HCQ in the lungs with pneumonia. That is, it might be proposed that the amount of HCQ could be less in the diseased lungs than in the healthy lungs (figure). Gradual HCQ accumulation in the lungs might also contribute to augmentation of the difference between concentrations of healthy and diseased lungs since the speed of the accumulation of HCQ in the diseased lungs might be slower than the speed of the progression of the pneumonia. According to the current literature, Covid-19

pneumonia is usually presented with bilateral scattered ground glass opacities and some consolidations ranging from minimal to extensive involvement of the lungs in chest CT scans³⁰⁻³³. The more advanced the disease might be the more radiologic involvement in covid-19 pneumonia³⁰⁻³³. Thus, treatment of advanced Covid-19 pneumonia patients with HCQ might result in significant sub-therapeutic drug concentrations in the lungs, which might cause treatment failures.

It is also possible that patients having minimal or limited pulmonary involvement might have less viral loads than patients having extensive lung involvement³⁴. This situation could also be valid for the proposed cytokine storm^{1,2,29,35} in Covid-19 pneumonia patients that might also have strong detrimental effects³⁵ on disease progression which could be prevented by HCQ since HCQ might also have beneficial immune modulatory effects^{1,2, 19-22}. However, as explained above, patients having extensive lung involvement might have less HCQ concentrations in their lungs than patients that of having limited lung involvement (figure), which could possibly be associated with some degree of treatment failure in patients with extensive Covid-19 pneumonia; that could also be translated as that HCQ might not be effective in treatment of advanced Covid-19 pneumonia cases considering together with HCQ's gradual onset of action.

Combining above data and assumptions, using HCQ in Covid-19 prophylaxis seems logical, since providing enough accumulation of HCQ in the healthy lungs, before the arrival of the SARS-CoV-2 virus and before the lung tissue became unsuitable for drug uptake due to pneumonia, might prevent Covid-19 pneumonia. In accordance with this hypothesis that in an experimental zika virus infection study in mice, chloroquine (CQ) was shown to be able to prevent zika virus induced mortality when it was used shortly after the infection (0 or 12 hours) however it did not show

any antiviral effect when used after 24 hours of infection³⁶. In an other study in mice, 50 mg/kg/ day CQ administration was made for two 2 days before zika virus infection and the same dosage for 5 days after the beginning of the infection, and 5 mg/kg/ until end of the experimental procedure. Control mice were administered only drinking water. It was shown that CQ provided a significantly longer lifespan and survival for zika virus infected mice and alleviated zika virus caused weight loss³⁷. In small studies with Covid-19 patients, it was also shown that HCQ treatment might be successful in treating mild and moderate Covid-19 cases^{4,5} whereas there is no study available showing a treatment success in severe or critical pneumonia cases for now.

Hypothesis

1-Since patients having extensive lung involvement might have more viral loads in their lungs than patients having limited lung involvement³⁴ and patients having extensive lung involvement might have significant sub-therapeutic drug concentrations in their lungs and, gradual HCQ accumulation in the lungs might also contribute to this phenomenon, treatment of advanced Covid-19 pneumonia patients with HCQ might result in treatment failure, on the contrary, patients with mild or moderate pneumonia might have therapeutic drug concentrations in their lungs and might show treatment success.

2-Since HCQ has a gradual onset of action in the treatment of rheumatic diseases²⁰⁻²³, which might also be valid for the treatment of Covid-19 pneumonia and there might be a likelihood of sub-therapeutic drug concentrations in the pneumonic areas of the lungs, beginning the administration of the HCQ before the disease establishment, that could be also translated as prophylaxis, seems logical. That is, providing enough accumulation of HCQ to achieve therapeutic/protective drug

concentrations in healthy lungs, before the arrival of the SARS-CoV-2 virus, might prevent Covid-19 pneumonia.

If the ongoing clinical trials show promising results at least in the treatment of mild and moderate Covid-19 pneumonia patients, HCQ might be proposed as a suitable candidate for a prophylactic drug in addition to its use in the treatment of Covid-19 pneumonia.

Frequency of Side Effects of HCQ; Is it Really Harmful in the Context of Covid-19 Treatment?

Currently, HCQ is used mainly for the treatment of rheumatic diseases. Hundreds of thousands of patients or more use HCQ worldwide for these diseases. Even though HCQ can cause many side effects, retinopathy was consistently investigated or reported according to a PubMed search (Accessed 16 April 2020) with the words (in the title) hydroxychloroquine and retinopathy (117 results). The other side effects searched and listed on PubMed (in the title) are hydroxychloroquine and cardiomyopathy (22 results), hydroxychloroquine and porphyria (12 results), hydroxychloroquine and psoriasis (11 results), hydroxychloroquine and heart (8 results) hydroxychloroquine and cardiac (7 results), hydroxychloroquine and QT (3 results), hydroxychloroquine and hypoglycemia (2 results), hydroxychloroquine and psychosis (2 results) hydroxychloroquine and depression (1 result), and hydroxychloroquine and side effects (4 results) respectively. These results suggest that the side effects other than retinopathy are very rare or not necessarily reported or they are underestimated or they are not seen as frequent as what should be theoretically expected or the combination of the aforementioned reasons. Retinopathy is a significant side effect however it might appear after consuming daily

HCQ doses regularly for a very long period of time, which is not absolutely comparable to the duration of treatment for covid-19 patients. However no drug is innocent, HCQ also has several significant side effects other than retinopathy such as QT prolongation, cardiomyopathy, hypoglycemia, neuro-psychiatric side effects, aggravation of psoriasis or porphyria^{18,22}. QT prolongation is considered as a potentially life-threatening side effect of HCQ however there are only three articles listed after the PubMed search with the words (in the title) hydroxychloroquine and QT. Even though conclusive evidence of cardiotoxicity caused by HCQ is not available from the current literature²² since it is a potentially life-threatening event and also combined use of certain drugs with HCQ theoretically increase drug toxicity, every single patient prone to QT prolongation should be examined in detail and carefully monitored before, during and after HCQ therapy. In addition, risk and benefit ratio should be determined for every single patient before using HCQ.

Conclusion

If the ongoing HCQ clinical trials show promising results at least in the treatment of mild and moderate covid-19 pneumonia patients, considering the risk and benefit ratio, in addition to its use in the treatment of Covid-19 pneumonia, HCQ could be a suitable candidate for the prophylaxis of Covid-19 pneumonia at least until a new vaccine or a confirmed new prophylactic drug is available.

Transparency Declarations: None to declare

REFERENCES

- 1 Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. *J Antimicrob Chemother.* 2020 20. pii: dkaa114.
- 2 Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov.* 2020; 18;6:16.
- 3 Yao X, Ye F, Zhang M, Cui C, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020 9. pii: ciaa237.
- 4 Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID - 19: results of an open - label non - randomized clinical trial. *International Journal of Antimicrobial Agents* – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949
- 5 Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Version 2. *medRxiv* 2020.03.22.20040758. [Preprint.] doi:10.1101/2020.03.22.20040758

6 Perinel S, Launay M, Botelho-Nevers É, et al. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients. *Clin Infect Dis.* 2020 Apr 7. pii: ciaa394. doi: 10.1093/cid/ciaa394.

7 Arnold SLM, Buckner F. Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection. *Clinical and Translational Science* <https://doi.org/10.1111/cts.12797>

8 COVID - 19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society - led International Task Force <https://www.thoracic.org/covid/covid-19-guidance.pdf> (Accessed 16 April 2020)

9 Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. *BMJ.* 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.

10 https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf (Accessed 16 April 2020)

11 https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf (Accessed 16 April 2020)

12 Indian Council for Medical Research. Recommendation for empiric use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection. https://icmr.nic.in/sites/default/files/upload_documents/HCQ_Recommendation_22M_arch_final_MM_V2.pdf. (Accessed 16 April 2020)

13 Kaushik N, Subramani C, Anang S, et al. Zinc Salts Block Hepatitis E Virus Replication by Inhibiting the Activity of Viral RNA-Dependent RNA Polymerase. *J Virol*. 2017 Oct 13;91(21). pii: e00754-17. doi: 10.1128/JVI.00754-17

14 Suara RO, Crowe JE Jr. Effect of zinc salts on respiratory syncytial virus replication. *Antimicrob Agents Chemother*. 2004 Mar;48(3):783-90.

15 Derwand R, MD, Scholz M. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win todays battle against COVID-19? *Preprints (www.preprints.org)* doi:10.20944/preprints202004.0124.v1

16 Popert AJ. Chloroquine: a review. *Rheumatol Rehabil*. 1976; 15(3):235-8.

17 McChesney EW, Banks WF Jr, Fabian RJ. Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat. *Toxicol Appl Pharmacol*. 1967; 10(3):501-13.

18 PLAQUENIL® HYDROXYCHLOROQUINE SULFATE TABLETS, USP
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf

19 Abarrientos C, Sperber K, Shapiro DL, et al. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. *Expert Opin Drug Saf*. 2011 Sep;10(5):705-14. doi: 10.1517/14740338.2011.566555.

- 20 Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. *Clin Pharmacokinet*. 1993 Nov;25(5):392-407.
- 21 Haładyj E, Sikora M, Felis-Giemza A, Olesińska M. Antimalarials - are they effective and safe in rheumatic diseases? *Reumatologia*. 2018;56(3):164-173. doi: 10.5114/reum.2018.76904.
- 22 Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol*. 2020 Mar;16(3):155-166. doi: 10.1038/s41584-020-0372-x.
- 23 Shukla AM, Wagle Shukla A. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. *Drugs Context*. 2019 Nov 25;8. pii: 2019-9-1. doi: 10.7573/dic.2019-9-1. eCollection 2019.
- 24 French JK, Hurst NP, O'Donnell ML, et al. Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy. *Ann Rheum Dis*. 1987; 46(1):42-5
- 25 Luo, W.; Yu, H.; Gou, J.; Li, X.; Sun, Y.; Li, J.; Liu, L. Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19). *Preprints* 2020, 2020020407
- 26 Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans. *medRxiv*.
doi: <https://doi.org/10.1101/2020.04.06.20050575>

- 27 Yuan A, Yang PC, Lee L, et al. Reactive pulmonary artery vasoconstriction in pulmonary consolidation evaluated by color Doppler ultrasonography. *Ultrasound Med Biol*. 2000; 26(1):49-56.
- 28 Björk L, McNeil BJ. Blood flow in pulmonary and bronchial arteries in acute experimental pneumonia and pulmonary embolism. *Acta Radiol Diagn (Stockh)*. 1977 Jul;18(4):393-9.
- 29 Hakim ST, Boyd FT, Soto JA. The Pathophysiology of Virulence of the COVID-19. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 7 April 2020
doi:10.20944/preprints202004.0077.v1
30. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology*. 2020 Feb 13:200370. doi: 10.1148/radiol.2020200370. [Epub ahead of print]
- 31 Shi H, Han X, Jiang N, Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis*. 2020 24. pii: S1473-3099(20)30086-4.
- 32 Zhang R, Ouyang H, Fu L, et al. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. *Eur Radiol*. 2020 Apr 11. doi: 10.1007/s00330-020-06854-1.

33 Liu KC, Xu P, Lv WF, et al. CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity. *Eur J Radiol.* 2020 Mar 12;126:108941. doi: 10.1016/j.ejrad.2020.108941.

34 MD, Park WB, Choe PG, et al. Viral Load Kinetics of MERS Coronavirus Infection. *N Engl J Med.* 2016 Sep 29;375(13):1303-5. doi: 10.1056/NEJMc1511695.

Oh

35 Shi Y1, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. *Cell Death Differ.* 2020 Mar 23. doi: 10.1038/s41418-020-0530-3.

36 Chunfeng Li, Xingliang Zhu, Xue Ji, et al. Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice *EBioMedicine.* 2017 Oct; 24: 189–194. Published online 2017 Sep 28. doi: 10.1016/j.ebiom.2017.09.034

37 Shiryaev SA, Mesci P, Pinto A, et al. Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis. *Sci Rep.* 2017 Nov 17;7(1):15771. doi: 10.1038/s41598-017-15467-6.